Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition

被引:22
作者
Blouin, Jean-Marc [1 ,2 ,3 ]
Bernardo-Seisdedos, Ganeko [4 ]
Sasso, Emma [1 ,2 ,3 ]
Esteve, Julie [1 ,2 ,3 ]
Ged, Cecile [1 ,2 ,3 ]
Lalanne, Magalie [1 ,2 ,3 ]
Sanz-Parra, Arantza [4 ]
Urquiza, Pedro [4 ]
de Verneuil, Hubert [1 ,2 ,3 ]
Millet, Oscar [4 ]
Richard, Emmanuel [1 ,2 ,3 ]
机构
[1] Univ Bordeaux, F-33000 Bordeaux, France
[2] INSERM, U1035, Biotherapie Malad Genet Inflammatoires & Canc, F-33000 Bordeaux, France
[3] Lab Excellence Gr Ex, Paris, France
[4] CIC BioGUNE, Prot Stabil & Inherited Dis Lab, Bizkaia Technol Pk,Bldg 800, Derio 48160, Spain
关键词
UROPORPHYRINOGEN-III SYNTHASE; PROTEIN STABILITY; MOLECULAR-DYNAMICS; IDENTIFICATION; GENE; EXPRESSION; ALGORITHM; GENOTYPE; SEQUENCE; SERVER;
D O I
10.1093/hmg/ddx067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Congenital erythropoietic porphyria (CEP) is an inborn error of heme biosynthesis characterized by uroporphyrinogen III synthase (UROS) deficiency resulting in deleterious porphyrin accumulation in blood cells responsible for hemolytic anemia and cutaneous photosensitivity. We analyzed here the molecular basis of UROS impairment associated with twenty nine UROS missense mutations actually described in CEP patients. Using a computational and biophysical joint approach we predicted that most disease-causing mutations would affect UROS folding and stability. Through the analysis of enhanced green fluorescent protein-tagged versions of UROS enzyme we experimentally confirmed these data and showed that thermodynamic instability and premature protein degradation is a major mechanism accounting for the enzymatic deficiency associated with twenty UROS mutants in human cells. Since the intracellular loss in protein homeostasis is in excellent agreement with the in vitro destabilization, we used molecular dynamic simulation to rely structural 3D modification with UROS disability. We found that destabilizing mutations could be clustered within three types of mechanism according to side chain rearrangements or contact alterations within the pathogenic UROS enzyme so that the severity degree correlated with cellular protein instability. Furthermore, proteasome inhibition using bortezomib, a clinically available drug, significantly enhanced proteostasis of each unstable UROS mutant. Finally, we show evidence that abnormal protein homeostasis is a prevalent mechanism responsible for UROS deficiency and that modulators of UROS proteolysis such as proteasome inhibitors or chemical chaperones may represent an attractive therapeutic option to reduce porphyrin accumulation and prevent skin photosensitivity in CEP patients when the genotype includes a missense variant.
引用
收藏
页码:1565 / 1576
页数:12
相关论文
共 44 条
[1]  
Anderson KE., 2001, Metabolic and molecular basis of inherited disease, V8 th, P2991
[2]   KINETICS VERSUS THERMODYNAMICS IN PROTEIN-FOLDING [J].
BAKER, D ;
AGARD, DA .
BIOCHEMISTRY, 1994, 33 (24) :7505-7509
[3]   Tuning intracellular homeostasis of human uroporphyrinogen III synthase by enzyme engineering at a single hotspot of congenital erythropoietic porphyria [J].
ben Bdira, Fredj ;
Gonzalez, Esperanza ;
Pluta, Paula ;
Lain, Ana ;
Sanz-Parra, Arantza ;
Manuel Falcon-Perez, Juan ;
Millet, Oscar .
HUMAN MOLECULAR GENETICS, 2014, 23 (21) :5805-5813
[4]  
BENSIDHOUM M, 1995, EUR J HUM GENET, V3, P102
[5]   Two brothers with mild congenital erythropoietic porphyria due to a novel genotype [J].
Berry, AA ;
Desnick, RJ ;
Astrin, KH ;
Shabbeer, J ;
Lucky, AW ;
Lim, HW .
ARCHIVES OF DERMATOLOGY, 2005, 141 (12) :1575-1579
[6]   Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria [J].
Blouin, Jean-Marc ;
Duchartre, Yann ;
Costet, Pierre ;
Lalanne, Magalie ;
Ged, Cecile ;
Lain, Ana ;
Millet, Oscar ;
de Verneuil, Hubert ;
Richard, Emmanuel .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (45) :18238-18243
[7]   CHARMM: The Biomolecular Simulation Program [J].
Brooks, B. R. ;
Brooks, C. L., III ;
Mackerell, A. D., Jr. ;
Nilsson, L. ;
Petrella, R. J. ;
Roux, B. ;
Won, Y. ;
Archontis, G. ;
Bartels, C. ;
Boresch, S. ;
Caflisch, A. ;
Caves, L. ;
Cui, Q. ;
Dinner, A. R. ;
Feig, M. ;
Fischer, S. ;
Gao, J. ;
Hodoscek, M. ;
Im, W. ;
Kuczera, K. ;
Lazaridis, T. ;
Ma, J. ;
Ovchinnikov, V. ;
Paci, E. ;
Pastor, R. W. ;
Post, C. B. ;
Pu, J. Z. ;
Schaefer, M. ;
Tidor, B. ;
Venable, R. M. ;
Woodcock, H. L. ;
Wu, X. ;
Yang, W. ;
York, D. M. ;
Karplus, M. .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2009, 30 (10) :1545-1614
[8]   I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure [J].
Capriotti, E ;
Fariselli, P ;
Casadio, R .
NUCLEIC ACIDS RESEARCH, 2005, 33 :W306-W310
[9]   Human uroporphyrinogen III synthase: NMR-based mapping of the active site [J].
Cunha, Luis ;
Kuti, Miklos ;
Bishop, David F. ;
Mezei, Mihaly ;
Zeng, Lei ;
Zhou, Ming-Ming ;
Desnick, Robert J. .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2008, 71 (02) :855-873
[10]   PARTICLE MESH EWALD - AN N.LOG(N) METHOD FOR EWALD SUMS IN LARGE SYSTEMS [J].
DARDEN, T ;
YORK, D ;
PEDERSEN, L .
JOURNAL OF CHEMICAL PHYSICS, 1993, 98 (12) :10089-10092